Figure 4. Pharmacological blockade of cPLAα by Efipladib impedes the growth of DLD-1 xenografts and decreases p-AKT levels in vivo.

(A) DLD-1 cells were inoculated into the flanks of nude mice. When xenograft tumours had reached 50 mm³ in volume, mice were randomised to control (n=7) or Efipladib treatment (7 mice/group) at a dose of 10 mg/kg i.p. daily for 14 days. Inhibition of tumour growth in the Efipladib-treated mice compared with the controls (p<0.001 by two way ANOVA with repeat measurement). ^*p<0.05 vs. control at the same day. (B) The fraction of Ki-67 positive cells was determined from the average number of positive cells in 10 high-power fields (×40). *p < 0.05 vs. control. (C) Xenografts were harvested, fixed and paraffin-embedded, and stained for Ki-67 by immunohistochemistry. Scale bar = 50 μm, magnification 200×. (D) Immunoblot of DLD-1 xenograft tumour and densitometry quantification. *p<0.05 vs. control, n=3. All data expressed as Mean ± SD.